AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Using Economic Profit to Assess Performance: A Metric for Modern Firms.

Business Horizons

| January 01, 2001 | Aggarwal, Raj | COPYRIGHT 2001 JAI Press, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

EP and other similar measures warrant the attention they have been receiving, particularly when supplemented by an appropriate non-financial measure.

Economic Profit (EP), Economic Value Added (EVA), Economic or Shareholder Value Increase (EVI or SVI), and other similar acronyms are becoming more and more popular for measuring and maximizing shareholder wealth. The calculation of these measures usually involves a number of adjustments to accounting data, but they are based on fairly simple concepts. Their displacement of accounting profits and widespread use in businesses seems surprisingly rapid.

The popularity of EP-type measures seems to be based on their contribution to solving the central problem of optimizing organizational architecture: Front-line personnel and first-level managers who have the best customer and operating information must be empowered and motivated to make decisions on maximizing shareholder value. Aligning shareholder, managerial, and operating personnel interests is a nontrivial problem that becomes more critical at lower levels of the hierarchy. Lower-level personnel generally find it harder than upper-level managers to relate to overall corporate profitability goals, but often have better information about business opportunities and related decisions. Moreover, losses or negative profits seem to receive more attention from front-liners than do shortfalls in profits from some target or goal. The internal use of EP-type measures can reduce such managerial and intra-firm agency problems by helping motivate people at all levels to make decisions that lead to returns in excess o f the cost of capital used.

This recent rise in the business use of EP-type measures is also consistent with the reengineering of the finance function away from a narrow technical role to that of a change agent. Contributing more widely to achieving strategic goals, the use of EP can also enlarge the role of finance by transforming corporate strategies into operating metrics useful for guiding and motivating managers and other employees. However, despite the importance of these measures in reducing intrafirm agency costs, this issue has received little attention.

What are the issues associated with the use of EP-type measures and their role in helping optimize the architecture of decision rights in a firm? What are their advantages and disadvantages? And how effective are they as internal performance metrics? For example, although they can be useful in reducing intrafirm and managerial agency costs, what about the need to ensure a focus on longterm value creation? Indeed, it is clear that the use of EP-type measures is not a substitute for continuing attention to the fundamental drivers of long-term value in a business. So how should a firm use EP and other such measures? And how should investors evaluate these efforts?

Economic Versus Accounting Profits

EP, SVI, and EVA all represent the net value added by the operations of a business over a given time period, usually a year. (A related measure, Market Value Added, or MVA, is often defined as the present value of future EPs.) Unlike accounting profits, all of these Firm Value Increase Measures (FVIMs) or Value Added Measures (VAMs) reflect the additional costs of both debt and equity capital used in operating the business:

Related articles from newspapers, magazines, journals, and more
Chain-type measures of real output and prices in the U.S. national income and...
Magazine article from: Business Economics Parker, Robert P. Triplett, Jack E. October 1, 1996 700+ words
...the present methodology as "chain type measures" of real GDP. Price measures for...comparing the newly released chain-type measures of real growth, which have no substitution...rates calculated using the chain-type measures with growth rates calculated using...
EP MedSystems Receives FDA Clearance for EP-WorkMate with RPM Catheter...
Press release article from: Business Wire August 27, 2003 700+ words
...Payment From Boston Scientific Corporation EP MedSystems, Inc. (NASDAQ:EPMD), a market leader in electrophysiology (EP) products used to diagnose and treat certain...Position Management(TM) technology with EP MedSystems' EP-WorkMate(R) workstation...
EP elastomers to be impacted by new technologies.
Magazine article from: Rubber World April 1, 1999 700+ words
Since they were commercialized in the early 1960s, EP elastomers - EPM and EP(D)M - have experienced no sudden breathtaking...gradually expanding the range of performance properties of EP elastomers. Technological changes have been incremental...
EP MedSystems Announces Japanese Regulatory Clearance for EP-4 Computerized...
Press release article from: Business Wire July 25, 2005 700+ words
WEST BERLIN, N.J. -- EP MedSystems, Inc. (NASDAQ: EPMD), a market...of Health, Labor and Welfare (MHLW) for its EP-4(TM) Computerized Cardiac Stimulator. With this clearance, EP MedSystems can now market and distribute the...
EP MedSystems Announces Canadian Regulatory Clearance for EP-4 Computerized...
Press release article from: Business Wire September 14, 2005 700+ words
WEST BERLIN, N.J. -- EP MedSystems, Inc. (NASDAQ: EPMD), a market...a license to allow the Company to market its EP-4(TM) Computerized Cardiac Stimulator. With this clearance, EP MedSystems can now market and distribute the...
EP MedSystems Announces FDA Market Clearance for New EP-4 Cardiac Stimulation...
Press release article from: Business Wire March 4, 2004 700+ words
...J.--(BUSINESS WIRE)--March 4, 2004 EP MedSystems, Inc. (NASDAQ: EPMD), a market...announced the FDA market clearance for its new EP-4(TM) Computerized Cardiac Stimulator. The EP-4 offers further advancements in cardiac stimulation...
EP MedSystems Reports Third Quarter Results.
Press release article from: Business Wire November 14, 2001 700+ words
...J.--(BUSINESS WIRE)--Nov. 14, 2001 EP MedSystems, Inc. (NASDAQ: EPMD) is pleased...existing pipeline of products and the current EP-WorkMate(R) platform which is a leader in EP labs with over 375 installations worldwide...
EP MedSystems Announces Changes to Its Board of Directors.
Press release article from: Business Wire January 11, 2007 700+ words
WEST BERLIN, N.J. -- EP MedSystems, Inc. (NASDAQ: EPMD), today...nervous system disorders. David Jenkins, EP MedSystems' Chairman stated, "We are...who passed away last week. David Bruce, EP MedSystems' President and CEO stated...
EP MedSystems Receives CE Mark for EP WorkMate and EP-3.
Press release article from: Business Wire August 21, 1998 700+ words
...BUSINESS WIRE)--Aug. 21, 1998--EP MedSystems Inc. (NASDAQ:EPMD) today...notified body to place the CE Mark on its EP WorkMate(TM) computerized electrophysiology workstation and the EP-3(TM) computerized electrophysiology...
EP MedSystems Receives Market Clearance from FDA for Constant Voltage EP-4...
Press release article from: Business Wire September 20, 2004 700+ words
WEST BERLIN, N.J. -- EP MedSystems, Inc. (NASDAQ: EPMD), a market leader in electrophysiology (EP) products used to diagnose and treat certain...clearance from the FDA for an enhancement to its EP-4 Computerized Cardiac Stimulator allowing...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA